Crystec provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries through application of the latest modified Supercritical Anti-Solvent (mSAS®) technology. We work with clients to help overcome development challenges, and apply the platform to our own assets.
Our services include enhanced polymorph screening, improving stability and generation of scalable co-crystals. The platform is an attractive, single-step alternative to conventional techniques (e.g. micronisation) in terms of process robustness, and ability to control the physical and solid-state properties of the most problematic compounds. mSAS is scaled to commercial GMP, facilitating a rapid transition from feasibility studies to clinical supply.